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Abstract
No commercial immunodiagnostic tests for human scabies are currently available, and existing animal tests are not
sufficiently sensitive. The recombinant Sarcoptes scabiei apolipoprotein antigen Sar s 14.3 is a promising immunodiagnostic,
eliciting high levels of IgE and IgG in infected people. Limited data are available regarding the temporal development of
antibodies to Sar s 14.3, an issue of relevance in terms of immunodiagnosis. We utilised a porcine model to prospectively
compare specific antibody responses to a primary infestation by ELISA, to Sar s 14.3 and to S. scabiei whole mite antigen
extract (WMA). Differences in the antibody profile between antigens were apparent, with Sar s 14.3 responses detected
earlier, and declining significantly after peak infestation compared to WMA. Both antigens resulted in .90% diagnostic
sensitivity from weeks 8–16 post infestation. These data provide important information on the temporal development of
humoral immune responses in scabies and further supports the development of recombinant antigen based
immunodiagnostic tests for recent scabies infestations.
Citation: Rampton M, Walton SF, Holt DC, Pasay C, Kelly A, et al. (2013) Antibody Responses to Sarcoptes scabiei Apolipoprotein in a Porcine Model: Relevance to
Immunodiagnosis of Recent Infection. PLoS ONE 8(6): e65354. doi:10.1371/journal.pone.0065354
Editor: E´rika Martins Braga, Universidade Federal de Minas Gerais, Brazil
Received January 28, 2013; Accepted April 25, 2013; Published June 6, 2013
Copyright:  2013 Rampton et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: KM is supported by an Australian Research Council Discovery Early Career Researcher Award (www.arc.gov.au). JMC is supported by an NHMRC
Practitioner Fellowship and Queensland Government Clinical Research Fellowship. This project was also supported by an NHMRC Project Grant (www.nhmrc.gov.
au). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kmounsey@usc.edu.au
Introduction
The ectoparasitic mite Sarcoptes scabiei causes a skin disease
referred to as scabies in humans and as sarcoptic mange in other
animal species. S. scabiei affects a wide range of animals worldwide,
with particularly vulnerable animals including pigs, dogs, camelid
species, wombats and koalas [1]. Scabies not only causes morbidity
due to the severe, persistent itch, but may also lead to secondary
infections, which can cause serious health complications [2,3]. In
animals, sarcoptic mange is associated with adverse welfare and
reproductive outcomes. For example, mange infestation is linked
to decreased testes mass and reduced reproductive capacity in
male Iberian ibex (Capra pyrnaica) [4], and both male and female
coyotes [5]. Mite antigens elicit inflammatory and allergic-type
reactions in the host that vary in clinical presentation. In humans,
ordinary scabies is characterised by a low mite burden (,15 mites
in total), intense pruritus, papular and vesicular lesions at the site
of infestation. In contrast, human crusted scabies is a rare,
debilitating manifestation, that entails the formation of hyperker-
atotic skin crusts containing an extremely high mite burden
(.1000 mites/g skin) [6]. In wild animals measuring the extent of
damaged skin may be useful proxy to evaluate mite burden [7].
Crusted scabies can be associated with immunosuppressive
conditions, such as HIV or HTLV-1 infection, following organ
transplantation, or induced by immunosuppressive drugs including
corticosteroids [8]. Importantly however, it is also observed in a
significant number of individuals with no overt immunosuppres-
sion or risk factor [9]. The immunopathology of scabies,
particularly crusted scabies, remains poorly understood [10]. Host
responses to S. scabiei are complex, with host species, previous
exposure, mite immunomodulation, individual susceptibility and
sex, all playing a likely role [11,12,13].
There are few methods to diagnose scabies that are sufficiently
sensitive, cost effective and convenient. The ‘‘gold standard’’ for
diagnosis is the identification of mites, eggs, or faeces from
scrapings of infested skin or by identification of mite burrows.
Despite 100% specificity, this method can have low sensitivity
(,50%) [14], as it relies on physically locating mites on the host,
problematic when mites are low in number. Clinical diagnosis can
be hindered by atypical manifestations, or symptoms that mimic
other skin conditions such as allergic dermatitis, or insect bites.
Thus, specificity of clinical diagnosis may lead to problems with
under or over diagnosis and inappropriate treatment of patients.
Alternate diagnostic methods for scabies include polymerase chain
reaction (PCR) [15], and dermoscopy [16,17], but these still rely
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on the ability to locate mites or mite DNA. These methods are also
not easily applied to clinical or public health settings.
The development of a reliable serologic method for diagnosis of
scabies, such as enzyme linked immunosorbent assay (ELISA),
would facilitate the control of scabies at both the individual and
community level. There is no commercially available ELISA for
the diagnosis of scabies in humans. ELISAs previously developed
for the detection of mange in animals utilise whole mite antigen
(WMA) extracts sourced from heavily infested animals, such as S.
scabiei var. vulpes sourced from foxes [18,19]. However, the
reported specificity and sensitivity of these tests is variable
[20,21]. Although variants of S. scabiei are morphologically similar
[22], they are predominantly host specific [23,24]. Cross reacting
proteins between different host variants have been identified via
immunoblotting [25], but there is usually insufficient cross
reactivity between host associated populations to use animal
derived WMA extracts for diagnosis of human scabies for example
[26,27,28]. Sourcing a S. scabiei var. hominis WMA extract for use
in a human scabies diagnostic ELISA is not feasible due to the
inability to undertake in vitro culture, and the low mite numbers in
most human infections. Therefore, development of an alternative
approach utilising S. scabiei recombinant antigens would be of
benefit.
In previous studies several recombinant proteins with immuno-
genic potential have been identified [29,30,31]. Of these, the
recombinant apolipoprotein Sar s 14 has emerged as a promising
immunodiagnostic candidate. A 400 amino acid region at the C-
terminus of this protein (Sar s 14.3), has been shown to elicit robust
IgG and IgE responses in patients with ordinary and crusted
scabies [32]. Recently, a quantitative IgE DELFIA using Sar s
14.3 showed 100% sensitivity in differentiating current scabies
infection from non-infected and previously exposed patients [33].
A limitation in the development and optimisation of serological
tests for scabies is the difficulty in rigorously defining the antibody
response at different stages of infestation, and accounting for
individual and host variability. Soluble extracts of S. scabiei have
been found to modulate expression of several cytokines and
lymphocyte surface molecules, which may result in down-
regulated antibody responses during infestation [34]. Thus, it
has not been determined at what point of infestation antibody
responses to recombinant antigens such as Sar s 14.3 can be
detected, or for how long antibody responses remain positive. In
primary scabies infestation, the incubation period can be up to 6
weeks [21], with the patient often unaware of infestation during
this period. This is of paramount importance in the clinical setting,
as earlier sensitive detection would facilitate improved treatment
and control by reducing transmission.
A tractable animal model of scabies has recently been utilised in
pigs [35]. The clinical manifestations and disease progression in S.
scabiei infested pigs closely resembles that of humans [36],
including the development of acute and chronic mange, akin to
ordinary and crusted scabies [37]. Thus our porcine model may be
useful in the testing and comparison of different immunodiagnostic
assays, providing leads to their use in both medical and veterinary
settings.
The aim of this study was to monitor the progression of the
porcine antibody response to scabies by measuring parasite-
specific immunoglobulin levels (IgG, IgG1, IgG2 IgA and IgM),
and to assess the suitability of the recombinant antigen Sar s 14.3
for diagnosis of porcine mange. We compared the diagnostic
sensitivity of the recombinant antigen Sar s 14.3 to S. scabiei WMA
extract, the current immunodiagnostic of choice for mange in
animals. Moreover, we explored potential correlations between
mange lesion severity and antibody responses. Dexamethasone
was used in this study to enhance infestation intensity; producing
clinical phenotypes akin to immunosuppression induced crusted
scabies [35]. This allowed us to study the effect of corticosteroids
on antibody responses in the presence and absence of mange.
These groups were compared with pigs infested with mites but not
treated with corticosteroids, which were expected to develop




Approval was obtained from the animal ethics committees of
the Queensland Institute of Medical Research (Approval number
1266) and the Queensland Department of Agriculture, Forestry
and Fisheries (Approval number SA 2009/07/294).
Animal Trial
This study was undertaken as part of a larger project exploring
scabies immunopathology in a porcine model, and was conducted
from 10th September 2009-March 2010. Twenty four three-week
old female piglets (Large White variety) were obtained from 7
parent sows. They were early weaned and randomly allocated to
one of four treatment groups (n = 6 per group). Group A: treated
daily with 0.25 mg/kg oral Dexamethasone (Dex) and ears
infected with approximately 2000 mites. Group B: ears infected
with approximately 2000 mites. Group C: treated daily with
0.25 mg/kg Dex (Dex only control). Group D: No Dex or mite
infection (negative control). Pigs were housed in four identical
indoor rooms, with a 12 hour light/dark photoperiod and constant
temperature of 24uC. Scabies infected and non-infected groups
were housed separately, and non-infected pigs sampled first, to
ensure that accidental transmission of mites did not occur. Dex
treatments and experimental scabies infestation of the ears were
carried according to protocols described previously [30], with S.
scabiei infested skin crusts obtained from our existing mange pig
model. The dose of 0.25 mg/kg dex was found to be sufficient to
maintain mite infestations while minimising adverse effects [35].
After baseline samples were obtained, pigs commenced on Dex
treatment for one week prior to mite infestation. The duration of
the trial was 24 weeks. Skin lesions from each pig were scored
weekly for clinical severity on a 1–8 scale (1 = mild papular rash
(resembling pimples), 2–4 = papular rash, plus increasing exudates,
red/inflamed skin, .4 = development of crusts, 8 = severe crusted
mange, with development of lesions external to ears). Skin
scrapings were collected from each pig fortnightly to approximate
mite numbers, as described previously [35]. Approximately 10 mL
of blood was collected from each pig fortnightly until week 12,
then at weeks 16, 20 and 24 post-infestation. Serum was isolated
by centrifugation at 3,000 g for 15 minutes, aliquoted and stored
at 280uC until required.
Source of Antigens
Whole Mite Antigen (WMA). Heavily infested skin crusts
were collected from mange infested pigs and S. scabiei var. suis
isolated from skin using a dissecting needle under microscopy.
Mites were stored in batches of 1,000–2,000 (approximately
10 mg) at 220uC until processing. To prepare antigen extracts,
100 mL of cold phosphate-buffered saline (PBS) was added to each
tube, vortexed for 5 minutes and pelleted by centrifugation at
10,0006g for 5 minutes. Mites were washed with 100 mL of cold
PBS with 1% sodium dodecyl sulfate (SDS) to remove adherent
host materials, and then centrifuged at 10,0006g for 5 minutes.
SDS residue was removed by washing twice with 100 mL of cold
Antibody Responses to Scabies
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PBS. Mites were homogenised in 100 mL of cold PBS, and
centrifuged at 10,0006g for 10 minutes. The homogenate was
filtered in a 0.22 mm centrifugal filter unit (Millipore Ultrafree GV
Durapore, Tullagreen) at 12,0006g for 3 minutes. Final protein
concentration was determined by measuring absorbance at
280 nm using the Nanodrop ND-1000 spectrophotometer (Nano-
drop Technologies, Wilmington, DE, USA). To determine
whether the presence of small amounts of host IgG within
WMA extracts could potentially confound results, we compared
standard WMA extracts with extracts that had been subjected to
IgG depletion (ProteoExtract Albumin/IgG removal kit, Merck
Millipore, Kilsyth, Australia). As no significant differences were
observed in serum binding between treated and untreated WMA
extracts (students T-test p = 0.94, Figure S1), routine IgG
depletion of WMA was not undertaken. The WMA preparations
were stored at 220uC for later use.
Sar s 14.3. S. scabiei var. hominis Sar s 14.3 recombinant
protein was expressed in Escherichia coli and purified as described
previously [32]. Aliquots were stored at 220uC and protein
concentration determined prior to use.
Evaluation of Similarity of Sar s 14.3 between Human and
Pig Derived S. scabiei
Sequence comparison. PCR was performed on S. scabiei var.
suis cDNA derived from a pool of mites using primers specific to
the S. scabiei var. hominis Sar s 14.3 fragment (F 59TCGAATGT-
GAAACGAAACAATG 39, R 59GTGCAAATATTGTCTGA-
TAGC 39). The PCR reaction contained 16PCR buffer, 0.4 mM
of each primer, 5 units of high-fidelity Taq polymerase (Hot Star
Taq, Qiagen, Doncaster, Australia), 2 mL template cDNA, and
dH20 to a final volume of 50 mL. PCR cycling conditions were:
Initial activation 95uC, 5 min; 35 cycles of 94uC, 15 s 60uC,
1 min, 72uC, 1 min 30 s; with final extension of 72uC, 5 min. The
PCR product was purified and sequenced. The resulting S. scabiei
var. suis Sar s 14.3 sequence was compared to the corresponding S.
scabiei var. hominis derived sequence (AF462196) by sequence
alignment using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/
clustalw2/).
Western blot. To determine cross-reactivity of var. hominis
Sar s 14.3 with mange infected pig sera, SDS PAGE was run with
WMA (5 mg) and Sar s 14.3 (2 mg). Resolved protein bands were
transferred to PVDF membranes, and blocked with 3% skim milk
powder (SMP) in PBS overnight at 4uC. Membranes were
incubated with sera collected from mange infected or non-infected
pigs, diluted 1:100 in 1% SMP-PBS, followed by goat-anti pig
IgG-AP secondary antibody, diluted 1:2000 (Abcam) using
standard western blotting methods [32]. Membranes were
developed and visualised using the phosphatase substrate BCIP/
NBT (Sigma-Aldrich).
Detection of Scabies Specific Antibodies by ELISA
Polystyrene plates (Greiner Bio-one) were coated at 4uC
overnight with either WMA diluted in carbonate buffer (0.1M
Na2CO3, pH 9.6) or Sar s 14.3 diluted in urea buffer (3M urea,
100 mM NaH2PO4, 10 mM Tris, pH 8.2), both at a concentra-
tion of 0.5 mg per well. Plates were washed twice with PBS with
0.5% Tween-20 (PBS-T) and blocked with 200 mL 1% Bovine
Serum Albumin (HyClone, Utah) in PBS-T, incubated at 4uC
overnight or 37uC for 2 hours, followed by washing twice with
PBS-T.
Test sera were diluted in PBS-T containing 0.8M NaCl, with
optimal dilutions for each antibody combination determined by
checkerboard titration. For WMA, sera were diluted 1/1000 for
detection of IgG, 1/100 for IgG1, IgG2 and IgM, and 1/20 for
IgA. For Sar s 14.3, sera were diluted 1/100 for detection of IgG,
IgG1 and IgM, 1/50 for IgG2, and 1/20 for IgA. Sera was
aliquoted in duplicate at 50 mL per well. To evaluate ELISA
performance and account for inter-assay variation, positive control
serum, diluted at the relevant test concentration, was included on
each plate. This control was derived from a pool of infected pigs,
previously shown to elicit strong reactivity in western blot and
ELISA. Additional controls included background (all antibodies
replaced with PBS), omission of primary antibody, and omission of
antigen. Plates were incubated at 37uC for 2 hours, and washed
five times with PBS-T.
Secondary antibodies used were: Rabbit anti-pig polyclonal
IgG-HRP (Sigma-Aldrich, 1/20,000); Mouse anti-pig monoclonal
IgG1 and IgG2 (Thermo Scientific, Rockford, 1/100 or 1/500);
Goat anti-pig IgA-HRP (Bethyl Laboratories, Montgomery, 1/
2000); Goat anti-pig IgM-HRP (Bethyl Laboratories, 1/2000). As
there is no porcine-specific IgE antibody commercially available,
IgE reactivity was not evaluated. Secondary antibodies were
diluted, incubated and washed as above. For detection of IgG1
and IgG2, a tertiary goat-anti mouse IgG-HRP antibody (Sigma,
1/500) was diluted, incubated, and washed as described above.
Substrate was prepared as per manufacturer’s instructions
(Sigma-Fast OPD, Sigma-Aldrich) and 200 mL added to each well.
Plates were developed in the dark for 30 minutes and read at
450 nm. To calculate optical density (OD), mean background
values were subtracted from test samples and duplicates averaged.
Corrected OD values were normalised by dividing by the positive
control OD to obtain a standardised ELISA unit.
Statistical Analysis
All analysis was carried out using GraphPad Prism version 5.0
(GraphPad Software, Inc.). Significance of differences between
groups were assessed by repeated measures two-way analysis of
variance (ANOVA), with Bonferroni post-tests to compare groups
at each time-point. As this test requires sample groups to be
matched (i.e. equal numbers across all time points), the first two
weeks were not tested due to missing or insufficient sera samples
for some pigs at these time points.
As a measure of potential diagnostic performance, sensitivity
and specificity was calculated on all ELISAs, at all time points.
Cut-offs were calculated at each week by taking the average of the
negative control group (group D) +2 Standard Deviations.
Sensitivity percentages were calculated using the following
formula: ELISA positive/scabies positive pigs 6 100, whereas
specificity percentages were calculated by: ELISA negative/scabies
negative pigs 6 100. Overall ELISA performance was also
compared using Receiver Operator Characteristic (ROC) curve
analysis, which provides detailed information about discrimination
between positive and negative samples, allowing determination of
optimal cut-offs by plotting assay sensitivity versus specificity
across a range of cut-off points. The ‘optimum’ is the cut-off where
the highest sensitivity and specificity is achieved. For this, IgG,
IgG1 and IgG2 assays were compared for WMA and Sar s 14,
using ELISA values obtained during peak of clinical infection
(weeks 8–20).
To assess if clinical phenotype was correlated with antibody
response, Spearman correlation coefficients were calculated
between the skin lesion scores and ELISA values from scabies
infected pigs over the peak of clinical infection (weeks 8–20). Due
to the possible confounding influence of Dex immunosuppression
on antibody response, pigs in the non-Dex treatment group were
assessed independently.
Antibody Responses to Scabies
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Results
Similarity and Cross Reactivity between S. scabiei var. suis
and var. hominis Sar s 14.3
Sar s 14.3 cDNA was PCR amplified from S. scabiei var. suis
using primers based on the S. scabiei var. hominis sequence. The
sequenced pig mite PCR product had 100% amino acid identity to
the human mite Sar s 14.3, and was submitted to Genbank
(Accession KC691249). Recombinant Sar s 14.3 derived from S.
scabiei var. hominis was recognised by sera from mange infected
pigs, with strong IgG binding to both Sar s 14.3 and the WMA
positive control (Fig. 1B). Non-infected pig sera reacted only
weakly with these antigens (Fig. 1C).
Clinical Progression of Mange Infection
A range of clinical manifestations were observed during the 24
week animal trial. Lesions were first detected in infected pigs at 3–
4 weeks post infection. Dexamethasone treatment accelerated
lesion development and severity, with crusted mange (lesion scores
4–8) observed in all Dex treated pigs from weeks 8 to 24 (Fig. 2A).
One pig in this group was euthanized at week 20 when clinical
severity reached AEC welfare criteria. Mange positive pigs not
receiving Dex treatment showed a range of clinical manifestations,
including acute and crusted mange (Fig. 2B). Most pigs in this
group showed a peak in lesion severity between weeks 8 and 12,
before a reduction in symptoms occurred from weeks 12–16, and
stabilising from weeks 16–24. Two pigs in this group developed
crusted mange despite the absence of corticosteroids. Pigs in the
non-infested groups did not develop skin lesions, nor were mites
recovered in skin scrapings at any time during the trial.
Development of Scabies-specific Antibodies during
Infection
Antibody Responses to Whole Mite Antigen (WMA). Pigs
from both mange positive groups developed robust IgG, IgG1 and
IgG2 responses to WMA extract. Statistically significant differ-
ences in specific IgG were evident in mange positive pigs
compared with non-infected pigs from week 10 post infection
and continued to week 24. Responses in IgG1 and IgG2 subclasses
were similar to IgG, but occurred slightly earlier, at week 8 (IgG1)
and week 6 (IgG2) post-infection (Figure 3-1, A–C). Levels of IgM
increased in all groups over the course of infection. At week 10
however, mange positive pigs had significantly increased levels
IgM (Fig. 3-1, D). In the mange positive pigs there was a trend
toward increased IgA levels, but this also only reached statistical
significance at week 10 (Fig. 3-1, E).
Antibody responses to Sar s 14.3. Significantly increased
IgG, IgG1 and IgG2 responses were observed to Sar s 14.3 in
mange positive pigs from weeks 6–12 post infection compared to
non-infected pigs (Fig. 3-2, A–C). In contrast to WMA, there was a
decline in IgG antibody levels to Sar s 14.3 occurring from around
weeks 12–16, although mange positive pigs could still be
differentiated from non-infected pigs. Like WMA, there were
increases in IgM against Sar s 14.3 in all groups, but no significant
differences between groups (Fig. 3-2, D). There were no significant
differences in the IgA response to Sar s 14.3 between treatment
groups, although a trend for increased IgA levels in the mange
positive groups could be observed (Fig. 3-2, E).
Effect of Dexamethasone Treatment on Antibody
Response
For some isotypes there appeared to be a trend towards a
slightly lower antibody response in the Dex positive, mange
negative pigs, but there were no statistically significant differences
in antibody responses in the Dex treated groups either in the
mange positive or non-infected groups (Fig. 3).
Correlation between Lesion Severity and Antibody Levels
in Mange Infected Pigs
Moderate positive correlations were observed in the anti-WMA,
IgA (r = 0.53, p = 0.003) and anti-Sar s 14.3, IgG1 (r = 0.52,
p = 0.006) ELISAs. Conversely, a negative correlation was
observed in anti-WMA IgG2 ELISA (r =20.5, p20.007) (Fig. 4).
There was no correlation observed for any other antigen/antibody
combinations.
Comparison of Diagnostic Sensitivity and Specificity of
WMA and Sar s 14.3
Only total IgG and its subclasses were considered here, as IgM
and IgA were not shown to be diagnostic in this study. Across peak
clinical infection both antigens gave excellent diagnostic sensitivity
and specificity (.90%). For WMA, 100% sensitivity was observed
from week 8 with IgG and IgG1 and from week 12 with IgG2.
Overall, the sensitivity of Sar s 14.3 ELISA was higher earlier in
infection than WMA. For example, for Sar s 14.3 IgG1, 45%
sensitivity was observed at week 2, and 83% at week 6. In contrast,
WMA IgG1 sensitivity at week 6 was only 50% (Table 1).
However, diagnostic sensitivity of Sar s 14.3 declined from week
16–20 post-infection. ROC analysis confirmed the good sensitivity
achieved over the course of clinical infection (Table 2). Area under
curve, an overall indicator of performance, was .90% for both
antigens, but was higher for the WMA ELISAs. For both antigens,
the IgG1 subclass gave the most sensitive detection, with 100% for
WMA, and 97% for Sar s 14.3 (Table 1).
Discussion
Diagnosis of scabies in humans and animals remains problem-
atic. Smets & Vercruysse [38] conducted a large prevalence survey
on mange in Belgium pig farms, and compared diagnostic
techniques, with identification of mites considered as the
‘‘definitive diagnosis’’. They found that clinical scoring of lesions
(Average Dermatitis Score, ADS) was the most useful for diagnosis
of mange in herds, but importantly, only 45% of ADS positive
Figure 1. IgG reactivity of S. scabiei whole mite antigen extract
(WMA) and Sar s 14.3 with porcine sera. A: 4–20% coomassie
stained SDS-PAGE gel loaded with lane 1: prestained molecular weight
marker, lane 2: WMA, 5 mg, lane 3: Sar s 14.3 (2 mg). Corresponding
Western Blots probed with sera from mange infected pigs (B) and non-
infected pigs (C).
doi:10.1371/journal.pone.0065354.g001
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animals were positive for mites in ear scrapings. Such results
highlight the present difficulty in diagnosing mange in individual
animals.
An alternative diagnostic method for scabies may be immuno-
diagnostic ELISA utilising S. scabiei recombinant antigens, with the
diagnostic potential of Sar s 14.3 recently demonstrated for human
scabies [33]. The objective of this study was to utilise a porcine
experimental model to compare Sar s 14.3 and S. scabiei var. suis
WMA ELISA diagnostic sensitivity over the course of infection,
and to investigate the effect of mange severity and corticosteroid
immunosuppression on antibody response.
Clinical manifestations in the porcine trial proceeded as
expected, with dexamethasone increasing infection severity and
duration. In the non-Dex pigs, we observed a clinical peak at 8–10
weeks, before most pigs had a decline in clinical score. This
temporal pattern of infection in pigs has been well documented
[37,39]. Two non-Dex pigs still developed crusted mange,
indicative of differences in individual susceptibility, although it is
important to note that these pigs were not siblings. The apparent
recrudescence of symptoms at week 24 in some of the non-Dex
pigs may represent reinfestation from heavily infested pigs, or
alternatively, a cumulative immunomodulatory effect exerted by
long term mite infestation causing a true clinical recrudescence.
Mites have been shown to secrete molecules which modulate
cytokine expression, and in particular Th1/Th2 balance
[14,34,40,41,42], however the effect of this on humoral immunity
or clinical outcome has not been clearly elucidated.
We confirmed a robust IgG response in pigs experiencing a
primary mange-infestation to both WMA and Sar s 14.3. In
previous studies the total IgG responses to S. scabiei WMA have
been explored, but here we extend understanding by defining
circulating IgG subclasses, IgM and IgA. Increased total IgG is
commonly observed with scabies infection [9,27]. In our study,
levels of WMA specific IgG, IgG1 and IgG2 started to increase
from weeks 6–8, and peak at week 12–16, before either declining
slightly or plateauing. Other studies in pigs, dogs and goats show a
similar progression, with antibody titres increasing slowly before
plateau [13,43,44,45,46]. IgG1 and IgG2 responses to WMA were
Figure 2. Lesion development in mange infected pigs. Ear lesions were scored weekly. Score of 1–4: acute mange with generalised rash and
papular lesions of increasing density, .4: development of increasing encrustment, 8: extensive encrustment spreading external to ears. A:
Comparison of treatment groups (n = 6 per group), error bars represent mean6SEM. B: Clinical variation in mange severity in individual pigs from the
non-Dex treatment group.
doi:10.1371/journal.pone.0065354.g002
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in accordance with that observed for total IgG, although elevation
was evident slightly earlier.
Total IgG, IgG1 and IgG2 responses to Sar s 14.3 were also
strong in infected pigs from weeks 6–12 post-infection. However,
unlike WMA where seropositivity persisted or declined slightly,
there was a marked decline in the response to Sar s 14.3 after week
12, and no significant differences between positive and negative
pigs was apparent at weeks 20–24. The reasons for this decline are
not immediately apparent. Age related factors might be possible,
but immunocompetence and adult comparable IgG levels in pigs
are reported to be achieved from weeks 8–10, after which total
IgG is stable or increases until about 25 weeks [47,48,49,50]. Few
studies have looked at the effect of longer term mange infestations
on humoral antibody responses. While it is tempting to speculate
that this was associated with the decline in lesion severity,
especially in the mange positive dex negative group, even pigs that
remained heavily infested had a decline in IgG antibodies. It is
possible that immunomodulation exerted by mites, or immunore-
sistance may cause a subsequent decrease in antibody levels
[12,13,27,34]. It has been shown that human subjects currently
uninfected but with previous scabies exposure do not react to this
antigen [32], and vaccination of rabbits with Sar s 14.3 failed to
induce protective immunity in S. scabiei challenge trials [29].
Taken together, our results provide support that Sar s 14.3
reactivity is transient and not allow a protective immune response
to scabies.
Another consideration of our study is that we used only female
animals in this trial. Sarasa et al found marked reductions in
antibody responses to both primary and secondary S. scabiei
exposure in male ibex compared to females [13]. Sex related,
hormonal linked, immunological differences have been observed
in many other parasitic infections [51] with males often having
increased susceptibility to disease. While it is uncertain whether
this can be extrapolated to other animals (and humans) infested
with sarcoptic mange, sex and exposure related differences in
scabies ELISA diagnostic sensitivity should be evaluated in future
studies.
As IgG subclasses diverged after speciation, ‘‘same name
subclass’’ function cannot be extrapolated among mammals
[52], so caution must be taken when comparing human and
porcine IgG subclass data. Porcine IgG isotype bias has been
described in relation to resistance and susceptibility to disease, with
IgG1 associated with allergic type 2, and IgG2 with cell mediated
type 1 immune responses [53]. Thus, in the context of Th1/Th2
directed responses, the IgG1:IgG2 ratio in pigs could be
considered analogous to an IgG4:IgG1 ratio in humans. The
development of crusted scabies in humans appears to be associated
with a non-protective Th2 response [10]. Our data give some
limited support to this hypothesis, as IgG1 levels in pigs were
positively correlated with lesion severity, whereas IgG2 levels were
inversely correlated.
A limitation to this study was that no porcine specific IgE
antibody is commercially available, although some authors have
shown that cross reactivity between human and porcine IgE exists
[54] [55]. Several human studies report increased total and Sar s
14.3 specific IgE in scabies [9,25,32], and the development of a
Sar s 14 ELISA for human scabies has focussed on detection of
IgE, rather than the more commonly utilised IgG, which was
considered a less specific marker of infection [32,33]. In contrast,
Figure 3. Isotype specific WMA (1) and Sar s 14.3 (2) antibody responses over 24 weeks for the four pig treatment groups. Error bars
represent mean6SEM. *: p,0.05, compared to group D (Dex 2/Mange -) (two way repeated measures ANOVA). The first two weeks were not tested
by ANOVA due to the requirement for matched numbers, and insufficient sera samples from some pigs.
doi:10.1371/journal.pone.0065354.g003
Figure 4. Correlation between lesion severity and antibody
response. Scatter plot showing lesion score and ELISA units from
mange infected pigs in the non-Dex treatment group from weeks 8–20
post infection. Each point represents the lesion score and antibody level
for an individual pig at a single time point. R: Spearmans correlation
coefficient.
doi:10.1371/journal.pone.0065354.g004
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IgE responses to scabies in other animals are variable. A lack of
IgE binding during primary infestation was observed in a
significant proportion of S. scabiei infected dogs [27] and sheep
[56], whereas in another study goats mounted a strong IgE
responses to both primary and repeated mite challenge [46]. IgE
responses also increased significantly in sheep during secondary
infestation [56].From this it appears that differences may exist
between the immune responses of humans and other animals to
scabies, and between primary and secondary infestations. Thus,
future ELISA design should consider the possibility of using
different secondary antibodies for diagnosis in medical and
veterinary settings.
Previous studies have reported conflicting results for scabies
associated IgA development. IgA is usually more abundant in
mucosal regions than in serum. Arlian [27,57] and Hill [58]
reported significant decreases in serum IgA in scabies infested
subjects compared to controls. Increased levels of IgA have been
found in scabietic lesions of pigs [59], so decreases in serum IgA
may reflect migration to the site of infection. Interestingly
however, Walton [32] showed significant increases in Sar s 14.3
specific IgA in sera from crusted scabies patients. Although
conclusions made from this data are limited, there was some trend
for increased WMA specific IgA in mange infected pigs,
particularly those in the dex treated group where high lesion
scores were observed. However this was only statistically
significant at week 10. Similarly in the non-dex, mange infected
pigs, a moderate, but statistically significant positive correlation
between lesion score and WMA IgA level was observed.
IgM is traditionally considered the first line of the humoral
immune response, and increased total IgM has been demonstrated
in scabies patients [27,57]. While we saw a trend for increased
IgM in mange infected pigs, this was only significant at week 10
with WMA. The upward trend observed for all groups is likely
non-specific, attributable to the low specificity and high avidity of
IgM, combined with the development of the pig immune system
which involves increasing total IgM [60]. The rate of IgM increase
is especially rapid during the first eight weeks [49,61].
At week 0, prior to experimental infection or treatment, high
antibody responses were observed in some pigs to Sar s 14.3. Pre-
trial testing showed that all parent sows of the pigs used in this
study tested negative for Sar s 14.3 antibodies (Figure S2). Unlike
humans, the placental barrier prevents immunoglobulins from
passing into the developing piglet, although high levels of ‘‘pre-
adaptive’’ IgG and IgA antibodies are obtained from colostrum
[60]. Kuhn [31] also reported that non-infected porcine sera gave
high reactivity to some recombinant S. scabiei proteins, and
attributed this to the fact that the recombinant proteins were
produced in E. coli, of which pigs have high levels of environmental
exposure. Notably, some piglets in our trial were treated for an
outbreak of scours (E. coli/diarrhoea) after room and pen
allocation, but prior to Dex treatment or infection. This was most
severe in the one of the two rooms allocated to mite negative
groups, with most individual pigs in this room recording high
baseline Sar s 14.3 ELISA ODs accordingly. Although the
recombinant protein used in this study was purified with nickel
affinity chromatography, these data may reflect a response to
residual E. coli contaminants. Indeed, some minor binding was also
observed to Sar s 14.3 in mange negative sera in the western blots.
This issue could be resolved in future studies by more stringent
purification, endotoxin testing and removal, or a different protein
expression system. Pre-absorption with E. coli extracts did not
successfully reduce background reactivity in previous experiments
[20].
Table 1. Sensitivity and Specificity of ELISA tests for IgG to Whole Mite Antigen extract (WMA) and Sar s 14.3.
IgG IgG1 IgG2
Week WMA Sar s 14.3 WMA Sar s 14.3 WMA Sar s 14.3
Sens (%) Spec (%) Sens (%) Spec (%) Sens (%) Spec (%) Sens (%) Spec (%) Sens (%) Spec (%) Sens (%) Spec (%)
0 0 100 0 100 0 100 0 100 0 100 0 100
2 0 100 0 100 18 83 45 100 0 100 20 100
4 0 100 0 100 25 100 25 100 8 100 18 100
6 58 100 67 100 50 100 83 100 75 100 67 100
8 100 100 100 100 100 92 100 100 92 100 100 92
10 100 100 100 100 100 100 100 100 92 100 100 82
12 100 100 92 92 100 80 100 100 100 92 50 100
16 100 100 83 100 100 100 100 100 100 100 33 100
20 83 100 64 100 100 100 58 100 100 100 33 100
24 100 100 10 100 100 100 0 100 100 91 0 100
doi:10.1371/journal.pone.0065354.t001
Table 2. Receiver Operator Characteristic (ROC) comparison
of sensitivity and specificity of ELISA tests for Whole Mite
Antigen extract (WMA) and Sar s 14.3 from week 8 to 20 post-
infestation.
WMA Sar s 14.3
IgG IgG1 IgG2 IgG IgG1 IgG2
AUCa 0.95 0.99 0.98 0.91 0.97 0.91
S.Eb 0.019 0.004 0.012 0.025 0.015 0.027
Cut-off 0.43 0.49 0.45 0.93 1.02 0.95
Sensitivityc 90% 100% 95% 90% 97% 87%
Specificityc 90% 90% 90% 70% 92% 91%
aAUC- area under curve.
bS.E- standard error.
cOptimum sensitivity and specificity determined at cut-off indicated.
doi:10.1371/journal.pone.0065354.t002
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Understanding the impact of corticosteroids on antibody
responses to scabies is of relevance, as crusted or atypical
presentations of scabies can often occur in corticosteroid treated
patients, and the ability of a scabies immunodiagnostic to correctly
identify these cases is important. Although the effect of
dexamethasone on the clinical development of mange was readily
apparent in this study, we saw very little difference in antibody
responses between mange infected, Dex treated and control
groups. Pigs have been reported to be less susceptible to Dex
treatment than other species. For example, Flaming [62] found
that IgG antibody responses were unaffected in Dex treated pigs,
despite receiving much higher doses (2–6 mg/kg) than used in our
study (0.2 mg/kg). Similarly, Dex did not inhibit serum IgE levels
in a mouse model of atopic dermatitis [63]. This is in contrast to
cattle, where low doses of Dex (0.04 mg/kg) decreased antibody
production [64].
Implications for Diagnostics
Previous studies have shown Sar s 14 is expressed at high levels
in scabies mites, is immunogenic, but has minimal cross-reactivity
to house dust mite specific antibodies [29,32,33]. It is presumed
that all host variants of S. scabiei possess this protein. Therefore Sar
s 14 has been proposed to be utilised in ELISA tests diagnosing
scabies mite infestation in all host species. We confirmed high
amino-acid similarity between S. scabiei var suis and var. hominis Sar
s 14.3, and demonstrated that sera from infected pigs recognised
the S. scabiei var. hominis derived recombinant protein. When
considering the suitability of Sar s 14.3 for diagnosis of mange in
other animals, or if using different recombinant proteins, it is
important to assess potential genetic differences between different
host derived mites. With the availability of whole genome
sequences possible in the future, this task will become more
straightforward.
ELISA based diagnosis using both WMA and Sar s 14.3 was
highly sensitive and specific for diagnosis of sarcoptic mange from
weeks 8–16 post-infection. A key difference between the antigens
was that Sar s 14.3 had higher sensitivity than WMA earlier in
infection, while WMA was more sensitive in late infection, but is
also known to persist in animals for some time after treatment.
Decreased sensitivity of S. scabiei WMA ELISA has been reported
in adult sows compared to piglets (50% compared to 80%) [65], so
age related factors or adaptive immunity may play a role in our
observations of declining Sar s 14.3. The fact that pigs were still
clinically infected at weeks 20 and 24, but antibodies to Sar s 14.3
had declined to normal by this time, may be a limitation for
diagnostic usefulness in long term or chronic infections. To
investigate this important issue in more detail, larger studies on
adult pigs need to be undertaken. It is also possible that a larger
protein fragment or fragments from Sar s 14, or a cocktail of
recombinant proteins may further improve sensitivity for long
term infections. Although it is important for an ELISA to detect
current infection with sufficient sensitivity, the lack of a prolonged
response to Sar s 14.3 could be considered an advantage if the
objective is to differentiate recent from not recent infestation.
While similar temporal studies in humans are not ethically
acceptable, monitoring the kinetics of antibody responses after
treatment and reinfection in both humans, and in our pig model,
would be of value.
Conclusion
In the absence of the availability of host specific whole mite
extracts for use in serodiagnostics, recombinant proteins represent
a sustainable option. Results from this study indicate that the S.
scabiei antigen Sar s 14.3 provides high sensitivity for recent clinical
sarcoptic mange infection. Although further assay optimisation
may be needed, we have now established that Sar s 14.3 may be a
promising tool for diagnosis of mange in both humans and pigs.
Supporting Information
Figure S1 Comparison of IgG ELISA utilising IgG
depleted and untreated mite extracts. To remove potential
contaminating host IgG from whole mite extracts, protein extracts
were passed through an IgG depletion column. Equal amounts of
depleted and non-depleted WMA extracts were used to coat wells
and total IgG ELISA done with pooled mange positive and
negative control sera using standard protocols. Results show mean
6SEM from two experiments. No significant differences in
binding were observed between extracts (p = 0.94, students T-test).
(TIF)
Figure S2 Testing of pre-trial parent sows by Sar s 14.3
IgG ELISA. Grey bars represent individual parent sows, Mange
infected (black bars) and non-infected (white bars) adult pigs were
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